1
|
Barone ME, Lim A, Woody M, Taklifi P, Yeasmin F, Wang K, Lewinski MK, Singh R, Stoneham CA, Jia X, Guatelli J. Adaptor Protein Complexes in HIV-1 Pathogenesis: Mechanisms and Therapeutic Potential. Viruses 2025; 17:715. [PMID: 40431726 PMCID: PMC12115986 DOI: 10.3390/v17050715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2025] [Revised: 05/12/2025] [Accepted: 05/13/2025] [Indexed: 05/29/2025] Open
Abstract
Adaptor protein (AP) complexes are critical components of the cellular membrane transport machinery. They mediate cargo selection during endocytosis and intracellular vesicular trafficking. Five AP complexes have been characterized (AP1-5), and together their roles extend to diverse cellular processes including the homeostasis of membranous organelles, membrane protein turnover, and immune responses. Human Immunodeficiency Virus type 1 (HIV-1) and other lentiviruses co-opt these complexes to support immune evasion and the assembly of maximally infectious particles. HIV-1 Nef interacts with AP1 and AP2 to manipulate intracellular trafficking and downregulate immune-related proteins such as CD4 and MHC-I. Vpu also co-opts AP1 and AP2, modulating the innate defense protein BST2 (Tetherin) and facilitating the release of virions from infected cells. The envelope glycoprotein (Env) hijacks AP complexes to reduce its expression at the cell surface and potentially support incorporation into virus particles. Some data suggest that Gag co-opts AP3 to drive assembly at intracellular compartments. In principle, targeting the molecular interfaces between HIV-1 proteins and AP complexes is a promising therapeutic approach. Blocking these interactions should impair HIV-1's ability to produce infectious particles and evade immune defenses, leading to novel antivirals and facilitating a cure.
Collapse
Affiliation(s)
- Maria Elena Barone
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Alexis Lim
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Madison Woody
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Parisa Taklifi
- Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32306, USA (X.J.)
| | - Fatema Yeasmin
- Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32306, USA (X.J.)
- Department of Chemistry and Biochemistry, University of Massachusetts, Dartmouth, MA 02747, USA
| | - Kequan Wang
- Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32306, USA (X.J.)
- Department of Chemistry and Biochemistry, University of Massachusetts, Dartmouth, MA 02747, USA
| | - Mary K. Lewinski
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Rajendra Singh
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Charlotte A. Stoneham
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| | - Xiaofei Jia
- Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32306, USA (X.J.)
| | - John Guatelli
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; (M.E.B.); (M.K.L.)
- VA San Diego Healthcare System, San Diego, CA 92161, USA
| |
Collapse
|
2
|
Tavares LA, Januário YC, daSilva LLP. HIV-1 Hijacking of Host ATPases and GTPases That Control Protein Trafficking. Front Cell Dev Biol 2021; 9:622610. [PMID: 34307340 PMCID: PMC8295591 DOI: 10.3389/fcell.2021.622610] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 06/07/2021] [Indexed: 12/22/2022] Open
Abstract
The human immunodeficiency virus (HIV-1) modifies the host cell environment to ensure efficient and sustained viral replication. Key to these processes is the capacity of the virus to hijack ATPases, GTPases and the associated proteins that control intracellular protein trafficking. The functions of these energy-harnessing enzymes can be seized by HIV-1 to allow the intracellular transport of viral components within the host cell or to change the subcellular distribution of antiviral factors, leading to immune evasion. Here, we summarize how energy-related proteins deviate from their normal functions in host protein trafficking to aid the virus in different phases of its replicative cycle. Recent discoveries regarding the interplay among HIV-1 and host ATPases and GTPases may shed light on potential targets for pharmacological intervention.
Collapse
Affiliation(s)
- Lucas A Tavares
- Department of Cell and Molecular Biology, Center for Virology Research, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Yunan C Januário
- Department of Cell and Molecular Biology, Center for Virology Research, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Luis L P daSilva
- Department of Cell and Molecular Biology, Center for Virology Research, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| |
Collapse
|
3
|
Viral Interactions with Adaptor-Protein Complexes: A Ubiquitous Trait among Viral Species. Int J Mol Sci 2021; 22:ijms22105274. [PMID: 34067854 PMCID: PMC8156722 DOI: 10.3390/ijms22105274] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/10/2021] [Accepted: 05/12/2021] [Indexed: 12/22/2022] Open
Abstract
Numerous viruses hijack cellular protein trafficking pathways to mediate cell entry or to rearrange membrane structures thereby promoting viral replication and antagonizing the immune response. Adaptor protein complexes (AP), which mediate protein sorting in endocytic and secretory transport pathways, are one of the conserved viral targets with many viruses possessing AP-interacting motifs. We present here different mechanisms of viral interference with AP complexes and the functional consequences that allow for efficient viral propagation and evasion of host immune defense. The ubiquity of this phenomenon is evidenced by the fact that there are representatives for AP interference in all major viral families, covered in this review. The best described examples are interactions of human immunodeficiency virus and human herpesviruses with AP complexes. Several other viruses, like Ebola, Nipah, and SARS-CoV-2, are pointed out as high priority disease-causative agents supporting the need for deeper understanding of virus-AP interplay which can be exploited in the design of novel antiviral therapies.
Collapse
|